CN1634105A - Breviscapine sublingual tablet and its preparing process - Google Patents
Breviscapine sublingual tablet and its preparing process Download PDFInfo
- Publication number
- CN1634105A CN1634105A CNA2004100795734A CN200410079573A CN1634105A CN 1634105 A CN1634105 A CN 1634105A CN A2004100795734 A CNA2004100795734 A CN A2004100795734A CN 200410079573 A CN200410079573 A CN 200410079573A CN 1634105 A CN1634105 A CN 1634105A
- Authority
- CN
- China
- Prior art keywords
- breviscapine
- water
- soluble filler
- lubricant
- surfactant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention discloses the Breviscapine sublingual tablet for treating cardiovascular diseases and its preparing process, while the preparation comprises (by weight ratio) 14.2-42.9% of breviscapine, 50.1-83.7% of water-soluble bulking agent, 0.1-2% of surface active agent, 1-3% of disintegrating agent, 0.5-1% of lubricating agent, and 0.5-1% of glidant. The sublingual tablet is prepared through wet method granulation.
Description
Technical field
The present invention relates to a kind of pharmaceutical dosage form of breviscapine, relate in particular to a kind of breviscapine sublingual tablet and preparation method thereof.
Background technology
Active component breviscapine in the Sublingual tablet extracts refining from Yunnan specialty medical material Erigeron breviscapus (Vant.) Hand.-Mazz. platymiscium Herba Erigerontis (Erigeron breviscapusvaut Hand Mazz) and obtains.Have the cerebral blood flow increasing amount, reduce cerebral vascular resistance, improve cerebral circulation, alleviate the arteriole spasm, improve effects such as blood-brain barrier permeability, antagonism myocardial ischemia reperfusion injury through pharmacological evaluation and clinical application proof.To hypertension, cerebral hemorrhage, cerebral thrombosis cerebral embolism polyneuritis, chronic Intraventricular membrane inflammation and sequela thereof have better curative effect to twentieth century, and rheumatism, coronary heart disease are also had certain curative effect through clinical verification.Bibliographical information it can slow down aging, and can obviously improve by the memory represents obstacle due to scopolamine, the ethanol etc., obviously strengthen learning capacity, act on close or to be better than brain slightly multiple plain; The plasma viscosity, erythrocyte that can reduce Cerebral Infarction Patients effectively overstocks, platelet aggregation rate and Fibrinogen; Can decreased heart rate, reduce myocardial contraction, blood vessel dilating, minimizing myocardial oxygen consumption, effect such as resist myocardial ischemia.The conventional tablet Chinese medicine needs the long period could stripping, and medicine time that plays a role is slow.
Summary of the invention
The objective of the invention is to have proposed a kind of breviscapine sublingual dosage forms and preparation method thereof, Sublingual tablet is the sublingual administration mode, medicine directly absorbs by the Sublingual mucosa brings into play general action, can make medicine avoid pipe intestinal digesting enzyme and liver first pass metabolism destruction to medicine, improve bioavailability, medicine is absorbed rapidly, bring into play drug effect rapidly.The filler that prescription adds is the adjuvant that is applicable to the diabetes patient, has therefore enlarged medicine and has been suitable for crowd's scope.
The present invention realizes by following technical method: 14.2%-42.9% breviscapine, 50.1%-83.7% water-soluble filler are sieved respectively, and fully mixing is standby in the back, join in the supplementary material of mix homogeneously after the 0.1%-2% surfactant is dissolved in an amount of ethanol, the system soft material granulation, dry granulate adds 1%-3% disintegrating agent, 0.5-1% lubricant, 0.5-1% fluidizer mixing tabletting promptly.
The present invention implements by following steps:
A. write out a prescription (1000)
Raw material: breviscapine 20g
Adjuvant: mannitol 40g
Xylitol 73g
Tween 80 1g
Carboxymethyl starch sodium 3g
Micropowder silica gel 1.5g
Magnesium stearate 1.5g
B. by the prescription proportioning, 20g breviscapine, 40g mannitol, 73g xylitol are crossed 80 mesh sieves respectively, fully add the ethanol system soft material that contains the 1g tween 80 behind the mixing, crossing 14 mesh sieves granulates, after 30 ℃-60 ℃ dryings, cross 16 mesh sieve granulate, add 3g carboxymethyl starch sodium, 1.5g micropowder silica gel, 1.5g magnesium stearate mixing tabletting promptly.
The water-soluble filler that the present invention relates to comprises following adjuvant: xylitol, mannitol, sorbitol.
The specific embodiment
Example 1
Prescription: breviscapine 20g
Mannitol 40g
Xylitol 73g
Tween 80 1g
Carboxymethyl starch sodium 3g
Micropowder silica gel 1.5g
Magnesium stearate 1.5g
Ethanol is an amount of
Method for making: 20g breviscapine, 40g mannitol, 73g xylitol are crossed 80 mesh sieves respectively, fully add the ethanol system soft material that contains the 1g tween 80 behind the mixing, crossing 14 mesh sieves granulates, after 30 ℃-60 ℃ dryings, cross 16 mesh sieve granulate, add 3g carboxymethyl starch sodium, 1.5g micropowder silica gel, 1.5g magnesium stearate mixing tabletting promptly.
Example 2
Prescription: breviscapine 40g
Mannitol 30g
Sorbitol 63g
Tween 80 1g
Carboxymethyl starch sodium 3g
Micropowder silica gel 1.5g
Magnesium stearate 1.5g
Ethanol is an amount of
Method for making: 40g breviscapine, 30g mannitol, 63g sorbitol are crossed 80 mesh sieves respectively, fully add the ethanol system soft material that contains the 1g tween 80 behind the mixing, crossing 14 mesh sieves granulates, after 30 ℃-60 ℃ dryings, cross 16 mesh sieve granulate, add 3g carboxymethyl starch sodium, 1.5g micropowder silica gel, 1.5g magnesium stearate mixing tabletting promptly.
Example 3
Prescription: breviscapine 60g
Mannitol 33g
Xylitol 40g
Tween 80 1g
Carboxymethyl starch sodium 3g
Micropowder silica gel 1.5g
Magnesium stearate 1.5g
Ethanol is an amount of
Method for making: 60g breviscapine, 33g mannitol, 40g xylitol are crossed 80 mesh sieves respectively, fully add the ethanol system soft material that contains the 1g tween 80 behind the mixing, crossing 14 mesh sieves granulates, after 30 ℃-60 ℃ dryings, cross 16 mesh sieve granulate, add 3g carboxymethyl starch sodium, 1.5g micropowder silica gel, 1.5g magnesium stearate mixing tabletting promptly.
Claims (2)
1. sublingual administration tablet that contains breviscapine, it is characterized in that containing the breviscapine that weight ratio is 14.2%-42.9%, the water-soluble filler of 50.1%-83.7%, the surfactant of 0.1%-2%, the disintegrating agent of 1%-3%, the lubricant of 0.5-1%, the fluidizer of 0.5-1%, described water-soluble filler comprises xylitol, mannitol, sorbitol, surfactant is a tween 80, disintegrating agent is a carboxymethyl starch sodium, lubricant is micropowder silica gel, and fluidizer is a magnesium stearate.
2. the preparation method of breviscapine sublingual tablet according to claim 1, this method comprises the steps:
(1) prescription (1000)
Raw material: breviscapine 20g
Adjuvant: water-soluble filler 113g
Tween 80 1g
Carboxymethyl starch sodium 3g
Micropowder silica gel 1.5g
Magnesium stearate 1.5g
(2) by the prescription proportioning, fully mixing was standby after breviscapine, water-soluble filler crossed 80 mesh sieves respectively, surfactant is dissolved in the supplementary material that joins mix homogeneously behind an amount of ethanol makes soft material, crossing 14 mesh sieves granulates, 30 ℃ of-60 ℃ of dryings, cross 16 mesh sieve granulate, add disintegrating agent, lubricant, fluidizer mixing tabletting promptly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2004100795734A CN1634105A (en) | 2004-11-23 | 2004-11-23 | Breviscapine sublingual tablet and its preparing process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2004100795734A CN1634105A (en) | 2004-11-23 | 2004-11-23 | Breviscapine sublingual tablet and its preparing process |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1634105A true CN1634105A (en) | 2005-07-06 |
Family
ID=34847131
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2004100795734A Pending CN1634105A (en) | 2004-11-23 | 2004-11-23 | Breviscapine sublingual tablet and its preparing process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1634105A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103127009A (en) * | 2011-12-02 | 2013-06-05 | 浙江永宁药业股份有限公司 | Carthamin yellow sublingual tablet and preparation method and application thereof |
-
2004
- 2004-11-23 CN CNA2004100795734A patent/CN1634105A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103127009A (en) * | 2011-12-02 | 2013-06-05 | 浙江永宁药业股份有限公司 | Carthamin yellow sublingual tablet and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1709229A (en) | Memantine hydrochloride orally disintegrating tablet and its preparing method | |
| CN1954814A (en) | Medical composite with co-action for treating gout and its preparation method | |
| CN1698790A (en) | Gastrodia tuber preparation and its preparing process | |
| CN100335055C (en) | Pitavastatin soluble tablet composition and preparation method thereof | |
| CN1806802A (en) | Pharmaceutical composition with acetaminopher, loratadine and pseudoephedrine sulfate as active ingredients, preparation method and uses thereof | |
| CN1989960A (en) | Andrographolide dispersed tablet | |
| CN1634105A (en) | Breviscapine sublingual tablet and its preparing process | |
| CN1899300A (en) | Medicinal composition using amino glucose hydrochloride and chondroitin sulfate as active components and its preparing method and use | |
| CN112618504B (en) | Medicinal composition containing erigeron breviscapus extract and borneol and preparation method thereof | |
| CN1739537A (en) | Cyclodextrin clathrate of breviscapine and its prepn | |
| CN1381259A (en) | Medicine for treating diseases of rectum and anus | |
| CN1698640A (en) | Compound powder of Roxithromycin and ambroxol hydrochloride sustained adequate for children, its prescription and preparation method | |
| CN1817348A (en) | Medicinal composition with glycosamine hydrochloride and cartilagin sulfate as active components, its preparation and use thereof | |
| CN1228051C (en) | Medicinal composition for treating cardiovascular disease | |
| CN1857296A (en) | Medicine composition with roxithromycin and ambroxol hydrochloride as active components and its preparing method and use | |
| CN1275590C (en) | Dispersion tablet containing ginkgo leaf extract | |
| CN1872055A (en) | Compound preparation of amoxicillin and ambroxol hydrochloride suitable to use for children, prescription and preparation method | |
| CN1245163C (en) | Puerarin dispersing tablet composition and its preparation method | |
| CN1742719A (en) | Bilobanoate oral-cavity disintegrating tablet and preparation method | |
| CN1330293C (en) | Fleabane oral disintegration tablet and its preparing process | |
| CN1615875A (en) | Dispersive tablet having allopurinol and benzbromarone | |
| CN1915226A (en) | Oral disintegration tablet of Loratadine ambroxol, and prepartion method | |
| CN1990012A (en) | Three-yellow dispersed tablet | |
| CN1994304A (en) | Compound orally disintegrating tablet containing loratadine and ambroxol and preparation process thereof | |
| CN1887289A (en) | Oral disintegrant tablet of total arasaponin and its prepn |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |